With the possibility of getting a large settlement from Par in 2014 (man, that is a long ways off) does Santarus use that revenue to acquire a late stage drug, develop partnerships like with Glumetza, or both? Curious what others think may happen as a result of that settlement and if that will be used to help alleviate the future losses of Zegerid and Glumetza when they go generic in (2016?).
From BoA/Merrill Conf pres:
"And so you start to look at strategically other companies out there that make sense to acquire, and they have assets or they have technologies that would be complimentary to what we're doing. Maybe have a platform technology, where you could get three or four products out of it. So that's what we're going to start to really accelerate."